ADVANTAGES & DISADVANTAGES OF TREATMENT OPTIONS CVD: Cardiovascular Death Management of Type 2 Diabetes American Diabetes Assn 2020 Update Based upon recent research findings, the American Diabetes Asson & Europiean Asson for the Study of Diabetes recently updated their consensus treatment recommendations (Buse et al, 2019) for the following subsets of patients with diabetes: High risk diabetic patients GLP-1 agonists & SGLT2 inhibitors to reduce CV & renal risk in high risk patients, without regard to patient HbA1c levels (baseline or target) High risk for atherosclerotic CV disease GLP-1 agonists GLP-1 agonists produce the greatest benefit against CV events Systolic heart failure (HFrEF) & chronic kidney disease (CKD) SGLT2 inhibitors SGLT2 inhibitors have the greatest benefit to prevent progression of CKD, reduce hospitalization for HF, and reduce CV events & CV death Patients with foot ulcers SGLT2 inhibitors a recommended treatment, after consideration of risk vs benefits 2021 ADA Treatment Guidelines Figure 10
Thats the level of nuance that CSP programs should standardize into training and recording protocols
If I were to play this theme as a Long/Short, which I think is possible because of the correlations between names that are affected positively and not positively
When infused back into the bloodstream, lifileucel finds cancer cells, recognizes them as abnormal and eliminates them
Here are a few tips: Stay hydrated to help your kidneys and digestion function normally
